Cargando…

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study

Vasomotor symptoms (VMS; eg, hot flashes, night sweats) are caused by a loss of thermoregulatory control. The thermoregulatory center in the brain is innervated by kisspeptin/neurokinin B/dynorphin (KNDy) neurons. The activity of KNDy neurons is stimulated by neurokinin 3 receptor (NK3R) activation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fraser, Graeme, Lederman, Samuel, Waldbaum, Arthur, Lee, Misun, Skillern, Laurence, Ramael, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554911/ http://dx.doi.org/10.1210/js.2019-OR33-6

Ejemplares similares

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
por: Fraser, Graeme L., et al.
Publicado: (2020)

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
por: Santoro, Nanette, et al.
Publicado: (2020)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

OR06-5 Fezolinetant for Treatment of Moderate-to-severe Vasomotor Symptoms Associated with Menopause: Results from a 52-week Study (Skylight 2)
por: English, Marci, et al.
Publicado: (2022)

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
por: Fraser, Graeme L, et al.
Publicado: (2021)

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial
por: Neal-Perry, Genevieve, et al.
Publicado: (2023)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

“Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause”
por: Shaukat, Ayesha, et al.
Publicado: (2023)

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
por: Johnson, Kimball A, et al.
Publicado: (2023)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)
por: Simon, James, et al.
Publicado: (2020)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER’S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms
por: Langley, Paul C
Publicado: (2023)

SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2019)

Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
por: Trower, Mike, et al.
Publicado: (2020)

Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women
por: Prague, Julia K, et al.
Publicado: (2019)

Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action
por: Prague, Julia K., et al.
Publicado: (2018)

PMON281 PERSISTENT VIRILIZATION AND VASOMOTOR SYMPTOMS IN A TRANSMAN 5-YEARS POST TESTOSTERONE WITHDRAWAL
por: Nemati, Maryam, et al.
Publicado: (2022)

Hops for Menopausal Vasomotor Symptoms: Mechanisms of Action
por: Abdi, Fatemeh, et al.
Publicado: (2016)

SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms
por: Santoro, Nanette, et al.
Publicado: (2019)

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

SAT-001 Clinically Meaningful Effects of E2/P4 Oral Capsule in Treating Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

Neurokinin 1 Receptor Antagonists for Pruritus
por: Alam, Majid, et al.
Publicado: (2021)

Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)
por: Simon, James A., et al.
Publicado: (2023)

Association of Menopausal Vasomotor Symptoms With Increased Bone Turnover During the Menopausal Transition
por: Crandall, Carolyn J, et al.
Publicado: (2011)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms
por: Singhal, Savita Rani, et al.
Publicado: (2016)

Vasomotor and physical menopausal symptoms are associated with sleep quality
por: Kim, Min-Ju, et al.
Publicado: (2018)

Psychosomatic and vasomotor symptom changes during transition to menopause
por: Augoulea, Areti, et al.
Publicado: (2019)

MON-387 Pheochromocytoma Masquerading as Vasomotor Menopausal Symptoms
por: Xhikola, Majlinda, et al.
Publicado: (2019)

Vasomotor Symptoms: More Than Temporary Menopausal Symptoms
por: Ryu, Ki-Jin, et al.
Publicado: (2020)

Premenstrual Disorders, Timing of Menopause, and Severity of Vasomotor Symptoms
por: Yang, Yihui, et al.
Publicado: (2023)

Editorial: Genitourinary syndrome of menopause
por: Eleutério Junior, José, et al.
Publicado: (2022)

Identifying potential causal effects of age at menopause: a Mendelian randomization phenome-wide association study
por: Magnus, Maria C., et al.
Publicado: (2022)

Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)
por: Hoveyda, Hamid R., et al.
Publicado: (2015)

Neurokinin-1 Receptor Antagonists against Hepatoblastoma
por: Muñoz, Miguel, et al.
Publicado: (2019)

Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
por: Umland, Elena M.
Publicado: (2008)

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
por: Hassan, Fatima, et al.
Publicado: (2023)

Ovarian Hyperthecosis: Hyperandrogenism in a Post-Menopausal Woman
por: Fayad, Christine, et al.
Publicado: (2021)

Genitourinary Syndrome of Menopause: Epidemiology, Physiopathology, Clinical Manifestation and Diagnostic
por: Sarmento, Ayane Cristine Alves, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mesr2ntqhep4o7h67fkk2ilkau